Collectively, these findings indicate that β2 but not β1-AR activation is required to mobilize Vγ9Vδ2+ T-cells to blood that can be expanded into a superior product with enhanced cytotoxic activity against human hematologic malignancies. The gene discussed is ADRB1; the disease is hematologic disorder.